Seven important updates for National Brain Tumor Awareness Month

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

National Brain Tumor Awareness Month is commemorated in May.

The observance is intended to recognize patients with brain tumors, the clinicians who treat them and the caregivers who support them. It also helps highlight the need for additional research and new, more effective therapies.

In conjunction with National Brain Tumor Awareness Month, Healio and HemOnc Today provide the following updates in brain cancer research and treatment.

• Continued ofranergene obadenovec (VB-111, VBL Therapeutics) monotherapy priming after progression with bevacizumab (Avastin, Genentech) combination treatment improved survival outcomes among patients with recurrent glioblastoma, according to results of a phase 1/phase 2 study. Read more.

• Partial or total resection appeared associated with longer OS compared with biopsy alone among a cohort of adults with brainstem high-grade gliomas. Read more.

• Maximal resection of the contrast-enhanced tumor appeared associated with longer OS among all subgroups of patients with glioblastoma. Read more.

• An international study of glioblastoma revealed a cellular pathway that appears to contribute to glioma stem cell spread and proliferation. The findings put forth a new paradigm for glioma stem cell regulation, according to the researchers. Read more.

• Twelve institutions across the United States and Canada formed a collaborative designed to improve long-term survival and quality of life for patients with malignant brain tumors. Read more.

• Plasma cell-free DNA appeared to be an effective biomarker for tumor burden and a viable prognostic tool for disease progression among newly-diagnosed patients with glioblastoma. Read more.

• Investigators from St. Michael’s Hospital and The Hospital for Sick Children in Toronto have determined that the transcriptional regulatory protein ID1 appears to maintain cancer stem cells in glioblastoma. Results suggest ID1 inhibition could lead to better treatment efficacy. Read more.